The aim of this health technology assessment (HTA) is to inform decision-making about the appropriate use of point-of-care (POC) cardiac troponin (cTn) testing. Policy questions such as appropriate settings (rural or remote, ambulance, hospital, emergency room), the timing of testing, and population suitable for POC cTn testing have been raised in Canadian jurisdictions. This HTA will address these questions by evaluating the diagnostic accuracy, clinical utility, and cost-effectiveness of POC cTn testing in patients presenting with acute coronary syndrome (ACS).

Contents

• INTRODUCTION
  • Cost of the Technology
• OBJECTIVES
• METHODS — CLINICAL REVIEW
  • Literature Search Strategy
  • Selection Criteria and Methods
  • Exclusion Criteria
  • Data Extraction
  • Critical Appraisal of Included Studies
  • Data Analysis and Synthesis Methods
• METHODS — ECONOMIC EVALUATION
  • Primary Economic Evaluation
  • Budget Impact Analysis
• REFERENCES
• APPENDIX 1 DATA EXTRACTION FORM FOR DIAGNOSTIC ACCURACY AND CLINICAL UTILITY REVIEW
• APPENDIX 2 PROPOSED MODEL SCHEMATIC FOR THE ECONOMIC EVALUATION OF POC CARDIAC TROPONIN TESTING

Suggested citation:

Point-of-care cardiac troponin testing in patients with symptoms suggestive of acute coronary syndrome – project protocol [Internet]. Ottawa: CADTH; 2015 Jun. (CADTH Optimal Use Report vol.5, no.1a). [cited yyyy mmm dd]. Available from: https://www.cadth.ca/point-care-troponin-testing-patients-symptoms-suggestive-acute-coronary-syndrome

This report is prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). This report contains a comprehensive review of existing public literature, studies, materials, and other information and documentation (collectively the “source documentation”) available to CADTH at the time it was prepared, and it was guided by expert input and advice throughout its preparation.

The information in this report is intended to help health care decision-makers, patients, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this report should not be used as a substitute for the application of clinical judgment in respect to the care of a particular patient or other professional judgment in any decision-making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of this report to ensure that its contents are accurate, complete, and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this report.

CADTH takes sole responsibility for the final form and content of this report. The statements, conclusions, and views expressed herein do not necessarily represent the view of Health Canada or any provincial or territorial government.

Production of this report is made possible through a financial contribution from Health Canada.

PROSPERO Registration Number: CRD42015023442